Others have applied new technologies for aGvHD diagnosis, underlining the need for advances in the ability to diagnose GvHD in patients undergoing allogeneic HSCT.23, 29, 30 A biomarker panel consisting of six proteins potentially involved in the pathogenesis of aGvHD (IL-2 receptor-α, tumor necrosis factor receptor-1, hepatocyte growth factor, IL-8, elafin, a skin-specific marker,23 and regenerating islet-derived 3-α)31 was established for serum using enzyme-linked immunosorbent assay. This evidence concerns the gene TNFRSF1A and graft versus host disease.